✦ LIBER ✦

GLP-1 receptor agonists and insulin: where are we now?

✍ Scribed by Cowan, Jenna; McKay, Gerry; Fisher, Miles

Book ID: 118765736
Publisher: Wiley (John Wiley & Sons)
Year: 2012
Tongue: English
Weight: 58 KB
Volume: 29
Category: Article
ISSN: 2047-2897
DOI: 10.1002/pdi.1720

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dopamine D1 receptor ligands: Where are

Dopamine D1 receptor ligands: Where are we now and where are we going

✍ Jing Zhang; Bing Xiong; Xuechu Zhen; Ao Zhang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB

The dopamine (DA) D(1) receptor is the most highly expressed DA receptor subtype among the DA receptor family. Although the first DA D(1) receptor selective ligand SCH-23390 (1) was introduced more than two decades ago, clinically useful D(1) receptor selective ligands are rare. A renewed interest w

ChemInform Abstract: Dopamine D1 Recepto

ChemInform Abstract: Dopamine D1 Receptor Ligands: Where Are We Now and Where Are We Going

✍ Jing Zhang; Bing Xiong; Xuechu Zhen; Ao Zhang 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 15 KB 👁 1 views

Inhaled insulin delivery – where are we

Inhaled insulin delivery – where are we now?

✍ Douglas B. Muchmore; Jeffrey R. Gates 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

Insulin-Like Factor 3: Where Are We Now?

✍ RICHARD IVELL; STEFAN HARTUNG; RAVINDER ANAND-IVELL 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 791 KB

Prevention of Insulin-dependent Diabetes

Prevention of Insulin-dependent Diabetes: Where Are We Now?

✍ Pozzilli, Paolo 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 783 KB

Combining GLP-1 receptor agonists with i

Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings

✍ J. J. Holst; T. Vilsbøll 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 590 KB